Lean Mass – Start
The Lean Mass – Start is a focused three-part research stack pairing the growth factor IGF-1 LR3 with the mechano-growth factor PEG-MGF and the synergistic repair duo BPC-157 + TB-500.
Curated for laboratory study of muscle protein signaling, satellite-cell activation and tissue recovery – three complementary research compounds in one set, bundled below their combined individual price.
Original price was: 270,00 €.230,00 €Current price is: 230,00 €.
A 3-part anabolic and recovery research stack: IGF-1 LR3, PEG-MGF and the BPC-157 + TB-500 repair pair.
What's included in this stack
Lean Mass - Start - Focused Anabolic and Recovery Research Stack
Description
Mechanism of Action
This research bundle investigates pathways central to muscle growth and tissue repair. IGF-1 LR3 is studied for sustained activation of the IGF-1 receptor and downstream PI3K/Akt/mTOR signaling, while PEG-MGF is researched for its role in satellite-cell proliferation and localized muscle repair. The BPC-157 + TB-500 pair is investigated for angiogenesis, actin regulation and connective-tissue recovery, together exploring complementary effects on anabolic signaling and structural repair in research models.
Benefits
- Enhanced Anabolic Signaling – IGF-1 LR3 and PEG-MGF are investigated for their roles in activating the PI3K/Akt/mTOR pathway, which influences protein synthesis and cellular growth in experimental models.
- Accelerated Tissue Repair – The BPC-157 + TB-500 combination is studied for its synergistic ability to accelerate the repair of muscle, tendon, and ligament injuries in research models.
- Satellite Cell Activation – PEG-MGF and IGF-1 LR3 are researched for their involvement in stimulating satellite cells, which are precursor cells important for muscle regeneration and adaptation.
- Improved Angiogenesis – The BPC-157 + TB-500 stack is investigated for its capacity to promote angiogenesis, enhancing the formation of new capillaries and blood flow in injured tissues.
- Reduced Inflammation – BPC-157 and TB-500 are studied for their synergistic ability to reduce inflammatory cytokines and mitigate oxidative stress markers in damaged tissues.
- Enhanced Structural Integrity – The BPC-157 + TB-500 combination is researched for stimulating collagen synthesis and extracellular matrix remodeling, contributing to denser tissue structures.
- Metabolic Signaling Influence – IGF-1 LR3 is investigated for its interaction with metabolic signaling networks, influencing glucose uptake and nutrient utilization at the cellular level.
- Cellular Survival Support – IGF-1 LR3 is studied for its influence on anti-apoptotic mechanisms, while BPC-157 and TB-500 provide systemic protective effects across multiple organs in experimental models.
Research Data
IGF-1LR3
| Study / Model | Reported effect |
|---|---|
| Rodent skeletal muscle model | ↑ myofiber hypertrophy and protein synthesis via IGF-1R activation |
| In vitro myoblast culture | ↑ proliferation and differentiation; enhanced Akt/mTOR signaling |
| Pharmacokinetic comparison vs native IGF-1 | Extended half-life and reduced IGFBP binding affinity |
| Cellular repair models | ↑ satellite cell activation and tissue regeneration markers |
| Glucose metabolism studies | ↑ peripheral glucose uptake; modulated insulin sensitivity |
| Anabolic signaling assays | Sustained receptor phosphorylation and downstream PI3K activation |
PEG-MGF
| Study / Model | Reported effect |
|---|---|
| Rodent skeletal muscle injury model | ↑ Satellite cell activation and accelerated myofiber regeneration |
| In vitro myoblast culture | ↑ Proliferation and delayed differentiation, expanding the myogenic pool |
| Mechanical overload model (rat) | ↑ Local IGF-1Ec splice variant signaling and hypertrophic response |
| Cardiac ischemia model | Reduced cardiomyocyte apoptosis and improved tissue recovery markers |
| Pharmacokinetic comparison (PEG-MGF vs native MGF) | Extended plasma half-life from minutes to several hours |
| Aged murine muscle model | Partial restoration of satellite cell responsiveness to mechanical stress |
| In vivo denervation/atrophy model | ↓ Muscle protein degradation markers; preserved fiber cross-sectional area |
BPC-157 + TB-500
| Study/model | Reported effect |
| Rat Achilles tendon transection | Faster collagen fiber alignment and fibroblast proliferation by day 7-10; tensile strength ~30-40% higher vs control. |
| Rodent medial collateral ligament injury | Improved ligament histology and biomechanical strength; reduced scar tissue density vs saline. |
| Skeletal muscle contusion (mouse) | Earlier myofiber regeneration with denser cross-linking and smaller necrotic zones by day 14. |
| Full-thickness skin wound (rodent) | ↑ capillary density and re-epithelialization rate; combined use outperforms single-peptide arms. |
| Angiogenesis assays (preclinical) | TB-500 ↑ VEGF signaling and endothelial migration; BPC-157 stabilizes vasculature → net ↑ perfusion. |
| Inflammation models (cell/rodent) | ↓ TNF-α, IL-6 and oxidative stress markers; pro-repair cytokine profile supports tissue remodeling. |
| Tendon fibroblast and ECM markers (in vitro) | ↑ fibroblast migration and collagen I/III organization; improved FAK-paxillin pathway signaling. |
| Peripheral nerve crush (rodent) | Trends toward faster functional recovery and axonal sprouting alongside improved local perfusion. |
| GI mucosal injury (rodent) | BPC-157 contributes gut barrier protection; pairing with TB-500 maintains microcirculatory flow. |
| Overuse/strain models (rodent) | Reduced time to functional recovery and lower edema scores; supports maintenance protocols. |
Stack Suggestions
This research bundle is suited for investigators exploring entry-level anabolic and recovery protocols, particularly the interplay between growth-factor signaling, satellite-cell activation and connective-tissue repair.
Pen Dosage Chart
IGF-1LR3
| IGF-1LR3 Pen 1 mg | |
|---|---|
| Volume | 1 mL |
| mg/mL | 1 mg/mL |
| Click-to-Dose | 1 click = 0.01 mg |
| Example(s) | 10 clicks = 0.1 mg |
PEG-MGF
| PEG-MGF Pen 5 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 2.5 mg/mL |
| Click-to-Dose | 1 click = 0.025 mg |
| Example(s) | 10 clicks = 0.25 mg |
BPC-157 + TB-500
| BPC-157 + TB-500 Pen 5 + 5 mg | |
| Volume | 2.0 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg; 50 clicks = 2.5 mg |
| BPC-157 + TB-500 Pen 10 + 10 mg | |
| Volume | 2.0 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.10 mg |
| Example(s) | 10 clicks = 1 mg; 25 clicks = 2.5 mg |
Dosage & Protocols Variations
IGF-1LR3
Standard Research Protocol
- Dose: 0.02 – 0.05 mg (= 2–5 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Baseline anabolic signaling and muscle growth models.
Therapeutic Research Protocol
- Dose: 0.05 – 0.1 mg (= 5–10 clicks)
- Duration: 4 weeks
- Frequency: Daily, post-training in targeted muscle groups
- Cycle Interval: 4 – 6 weeks off before repeating
- Goal / Description: Higher-dose protocol for hypertrophy and cellular repair studies.
Stacked Protocol (IGF-1 LR3 + CJC-1295/Ipamorelin)
- Dose: 0.02 – 0.04 mg IGF-1 LR3 (= 2–4 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Combined GH and IGF-1 axis stimulation for anabolic research.
PEG-MGF
Standard Research Protocol
- Dose: 0.2 – 0.4 mg (= 8–16 clicks)
- Duration: 4 – 6 weeks
- Frequency: 2 – 3× per week
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Baseline protocol for muscle regeneration and satellite cell activation models.
Therapeutic Research Protocol
- Dose: 0.4 – 0.6 mg (= 16–24 clicks)
- Duration: 6 – 8 weeks
- Frequency: 3× per week post-training
- Cycle Interval: 4 – 6 weeks off before repeating
- Goal / Description: Higher-dose schedule used in hypertrophy and localized repair research.
Biohacker Protocol (experimental)
- Dose: 0.1 – 0.2 mg (= 4–8 clicks)
- Duration: 8 – 12 weeks
- Frequency: 2× per week
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Lower-dose continuous design exploring sustained anabolic signaling.
BPC-157 + TB-500
Standard Research Protocol
- Dose: 0.5 – 1 mg (variant 5 + 5 mg pen = 10–20 clicks / variant 10 + 10 mg pen = 5–10 clicks)
- Duration: 4 – 6 weeks
- Frequency: 1× daily
- Cycle Interval: 4 week rest
- Goal / Description: Basic tissue recovery support model
Enhanced Regeneration Protocol
- Dose: 1 – 1.5 mg (variant 5 + 5 mg pen = 20–30 clicks / variant 10 + 10 mg pen = 10–15 clicks)
- Duration: 8 – 12 weeks
- Frequency: Every other day
- Cycle Interval: 4 week rest
- Goal / Description: Designed for extended regenerative studies, emphasizing vascular and muscular adaptation
Post-Load Model
- Dose: 2 mg (variant 5 + 5 mg pen = 40 clicks / variant 10 + 10 mg pen = 20 clicks)
- Duration: 2 – 4 weeks
- Frequency: 1× daily
- Cycle Interval: 2 week rest
- Goal / Description: Applied in post-strain or high-load experimental recovery
Biohacker Protocol
- Dose: 0.5 mg (variant 5 + 5 mg pen = 10 clicks / variant 10 + 10 mg pen = 5 clicks)
- Duration: Continuous
- Frequency: 5× weekly
- Cycle Interval: 2 week rest
- Goal / Description: Experimental long-term maintenance design emphasizing consistent angiogenic response
Possible Side Effects
This bundle combines multiple research compounds; the per-compound safety notes below apply. For laboratory research use only – not for human consumption.
IGF-1LR3
IGF-1 LR3 is generally tolerated in research models, but several effects have been reported in experimental and observational data:
- Hypoglycemia due to insulin-like activity on glucose uptake.
- Localized swelling, redness, or discomfort at injection site.
- Transient headaches or lightheadedness during initial dosing.
- Joint pain or muscle cramps in prolonged research protocols.
- Potential organ enlargement with extended high-dose exposure in animal models.
No evidence of acute toxicity has been observed at standard research doses, though long-term effects on cellular proliferation remain under investigation.
PEG-MGF
PEG-MGF is generally well-tolerated in preclinical research and limited experimental human observations.
Reported side effects are uncommon and typically mild:
- Localized redness, swelling, or irritation at the injection site.
- Transient hypoglycemia-like symptoms due to IGF-1 pathway activation.
- Mild fatigue or lethargy shortly after administration.
- Occasional headache or lightheadedness in sensitive subjects.
- Possible localized muscle tightness near the injection area.
No evidence of severe hormonal, cardiovascular, or hepatic adverse effects has been observed in available research data. Long-term safety profiles remain under investigation, particularly regarding sustained IGF-1 receptor activation and tissue-specific growth signaling.
BPC-157 + TB-500
The BPC-157 & TB-500 blend, as research peptides involved in regeneration, may elicit side effects in experimental models, mainly at injection sites or systemically. Effects are typically mild and dose-related, with subcutaneous administration sometimes causing local responses. Close monitoring is essential.
Injection Site Reactions: Common observations include redness, swelling, or pain at the site, resolving within days. Rotating areas and proper technique minimize this.
Nausea or Gastrointestinal Upset: Mild queasiness may occur, linked to BPC-157’s gastric origins, especially at higher doses. It subsides with adaptation.
Fatigue or Dizziness: Transient lethargy has been noted early on, possibly from metabolic shifts or inflammation reduction. This resolves as models stabilize.
Headache: Occasional mild headaches, attributed to vascular changes from angiogenesis promotion.
Most side effects are transient and manageable via dose adjustment in research. Limited data suggest vigilance for potential long-term effects like overgrowth, though rare in controlled animal studies.
Product Attributes
Scientific References
IGF-1LR3
- Long-R3-IGF-I is potent in stimulating insulin-like growth factor receptor-mediated effects in cultured cells In vitro
- Insulin-like growth factor 1 (IGF-1): a molecular brake on aging and a tumor’s best friend? Animal | In vitro
- Skeletal muscle hypertrophy and atrophy signaling pathways Animal | In vitro
- The role of insulin-like growth factor-1 in the physiology of skeletal muscle Animal | In vitro
- Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function Animal
- IGF-1 signaling pathways in skeletal muscle hypertrophy Animal | In vitro
- Production, purification and characterization of recombinant Long-R3-IGF-I In vitro
- Insulin-like growth factor I and bone Animal | Observational
PEG-MGF
- Mechano-growth factor stimulates the proliferation but not the differentiation of myoblasts Animal | In vitro
- The expression of IGF-I splice variants in young and old human skeletal muscle Observational
- Mechano-growth factor induces hypertrophy of adult myocytes via the alpha7 integrin Animal | In vitro
- The role of mechano growth factor in skeletal muscle hypertrophy and regeneration Animal | In vitro
- PEGylation of mechano growth factor extends serum half-life and improves activity Animal | In vitro
- Mechano growth factor E-peptide promotes proliferation and migration of stem cells In vitro
- IGF-I splice variants in skeletal muscle in response to mechanical stimulation Animal
- Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch In vitro
BPC-157 + TB-500
- Intra-articular injection of BPC 157 for multiple types of knee pain Animal
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon Animal
- BPC157 as potential agent rescuing from cancer cachexia In vitro
- Thymosin β4: a multi-functional regenerative peptide Animal
- Pentadecapeptide BPC 157 cream improves burn-wound healing Animal
- Pentadecapeptide BPC 157 enhances the growth hormone receptor expression In vitro
- Emerging use of BPC-157 in orthopaedic sports medicine Observational
- Pharmacokinetics, distribution, metabolism, and excretion of body protective compound-157 Animal
- Novel wellbeing and repair peptide use in the UK Observational
- BPC 157 | 137525-51-0 – ChemicalBook In vitro
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
